Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 1.00 |
| ▸ | PPARA | Q07869 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040256 | 0.89 | PPARG (0.80) | PPARGPPARANPC1RAB9AMEN1 | |
| SCHEMBL7038671 | 0.88 | PPARG (0.78) | PPARGPPARANPC1RAB9AMEN1 | |
| SCHEMBL7036249 | 0.86 | PPARG (0.75) | PPARGPPARANPC1RAB9AMEN1 | |
| Lithium Ion SCHEMBL7034035 | 0.84 | PPARG (0.81) | PPARGPPARA | |
| Lithium Ion SCHEMBL7040859 | 0.82 | PPARG (0.70) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| Lithium Ion SCHEMBL7038912 | 0.82 | PPARG (0.82) | PPARGPPARA | |
| Lithium Ion SCHEMBL7042105 | 0.80 | PPARG (0.67) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| Lithium Ion SCHEMBL7039324 | 0.79 | PPARG (0.84) | PPARGPPARAMEN1KMT2A | |
| Lithium Ion SCHEMBL7034509 | 0.78 | PPARG (0.69) | PPARGPPARA | |
| Lithium Ion SCHEMBL7038537 | 0.78 | PPARG (0.64) | PPARGPPARANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885NPC1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.